Forkhead box L2 is a target of miR ‐133b and plays an important role in the pathogenesis of non‐small cell lung cancer
Cancer Medicine · 2023
DOI: 10.1002/cam4.5746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Juan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Forkhead box L2 (FOXL2) has been recognized as a transcription factor in the progression of many malignancies, but its role in non‐small cell lung cancer (NSCLC) remains unclear. This research clarified on the role of FOXL2 and the specific molecular mechanism in NSCLC.
Methods
RNA and protein levels were detected by quantitative real‐time polymerase chain reaction (qRT–PCR) and western blotting assays. Cell proliferation was examined by cell counting kit‐8 (CCK‐8) and clonogenic assays. Transwell and wound healing assays were used to detect cell invasion and migration. Cell cycle alterations were assessed by flow cytometry. The relationship between FOXL2 and miR‐133b was verified by dual‐luciferase reporter assays. In vivo metastasis was monitored in the tail vein‐injected mice.
Results
FOXL2 was upregulated in NSCLC cells and tissues. Downregulation of FOXL2 restrained cell proliferation, migration, and invasion and arrested the cell cycle of NSCLC cells. Moreover, FOXL2 promoted the epithelial–mesenchymal transition (EMT) process of NSCLC cells by inducing the transforming growth factor‐β (TGF‐β)/Smad signaling pathway. miR‐133b directly targeted the 3′‐UTR of FOXL2 and negatively regulated FOXL2 expression. Knockdown of FOXL2 blocked metastasis in vivo. Conclusions miR‐133b downregulates FOXL2 by targeting the 3′‐UTR of FOXL2, thereby inhibiting cell proliferation, EMT and metastasis induced by the TGF‐β/Smad signaling pathway in NSCLC. FOXL2 may be a potential molecular target for treating NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Suzhou Key Laboratory for Respiratory Diseases, Suzhou, China.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, China.
- Institute of Respiratory Diseases, Soochow University, Suzhou, China.
- Jiangsu Institute of Hematology, MOH Key Laboratory of Thrombosis and Hemostasis, Collaborative Innovation Center of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Zeyi Liu
Zitieren
APA
Li, J., Gao, L., Wang, A., Qian, H., Zhu, J., Ji, S., Chen, J., Liu, Z., & Ji, C. (2023). Forkhead box L2 is a target of miR ‐133b and plays an important role in the pathogenesis of non‐small cell lung cancer. Cancer Medicine. https://doi.org/10.1002/cam4.5746
Vancouver
Li J, Gao L, Wang A, Qian H, Zhu J, Ji S, et al. Forkhead box L2 is a target of miR ‐133b and plays an important role in the pathogenesis of non‐small cell lung cancer. Cancer Medicine. 2023. doi:10.1002/cam4.5746
BibTeX
@article{Li2023,
author = {Li, Juan and Gao, Lirong and Wang, Anqi and Qian, Huiwen and Zhu, Jianjie and Ji, Shundong and Chen, Jun and Liu, Zeyi and Ji, Cheng},
title = {Forkhead box L2 is a target of miR ‐133b and plays an important role in the pathogenesis of non‐small cell lung cancer},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5746}
}
EUVIMED